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1 BACKGROUND 
1.2 General 
The World Health Organisation's Special Programme for 
Research and Training in Tropical Diseases was initi- 
ated in 1975. Its purpose is to develop methods for 
controlling a number of tropical diseases and to 
strengthen the research capability of the countries 
affected. From its inception, Sweden has provided 
extensive support to the Programme. SAREC has dis- 
bursed a total of MSEK 102 from its budget, and in 
1985 appointed a special working group to review and 
follow up the Programme's activities. 
The review was aimed, with SAREC's goal of support- 
ing research in developing countries as a starting 
point, to take up various issues in order to assess 
how far the Programme corresponded to SAREC's 
requirements. The issues selected for special 
attention were: 
(a) The intradisciplinary quality of research 
activities. 
(b) The orientation and results of research, and its 
utility in relation to existing health problems, 
resources, priorities and health care policy in 
developing countries. 
(c) The Programme's potential in strengthening 
research capability (institutional support, 
research training, etc.). 
(d) The timescale of the Programme and its position 
in relation to WHO's regular activities. 
(e) The social-scientific and epidemiological com- 
ponents of the Programme and their integration 
with research activities; efforts to promote 
popular participation in control programmes. 
(f) Collaboration with industry and issues concern- 
ing patents. The position of the Programme in 
relation to other donors. 
(g) Funding channels, including earmarked grants 
e.g. for field studies. 
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1.2 Outline of SAREC's review 
The Terms of Reference for SAREC's review of the 
Special Programme for Research and Training in 
Tropical Diseases in 1985 are enclosed (App. 1). The 
evaluation was conducted as follows: 
(a) A systematic review of Programme documentation 
was conducted by the SAREC Secretariat and 
members of SAREC's advisory scientific consul- 
tant group (App. 2). 
(b) Working group members paid visits to several 
developing countries, in order to try and assess 
how the Programme helps these countries, against 
the background of existing health problems and 
resources. 
Large-scale reviews were conducted in Ethiopia 
and Zambia; in Somalia, Nicaragua and Cuba 
small-scale surveys of current research on 
tropical medicine took place (Apps. 3, 4, 5, 6, 
7). 
(c) Several members of the SAREC working group and 
representatives of the SAREC Secretariat visited 
the Programme's Geneva headquarters in June to 
obtain up-to-date information (App. 8). 
(d) A draft report was discussed at a meeting of the 
working group at the end of August 1985. A 
joint meeting with members of SAREC's working 
groups for two other SAREC-supported research 
programmes in WHO (research on human reproduc- 
tion and primary health care) took place on 16th 
September 1985. SAREC then produced reports on 
the three research programmes and proposals for 
joint support to health research under the aegis 
of WHO, for presentation to the SAREC's govern- 
ing board in the autumn of 1985. 
2 THE SPECIAL PROGRAMME - DESCRIPTION AND COMMENTS 
2.1 Qriglh? of the Programme 
During the 1960s and '70s, the severe health problems 
posed by infectious tropical diseases in many devel- 
oping countries became increasingly apparent. It was 
realised that existing methods for controlling these 
diseases were inadequate and that the accelerated 
progress of medical research since the Second World 
War had not had any appreciable impact on this group 
of diseases. This realisation was one of the points 
of departure for the discussions leading to the 
inception of the Special Programme for Research and 
Training in Tropical Diseases in the mid-1970s. The 
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Programme should, It was agreed, concentrate on the 
following six diseases: malaria, schistosomiasis 
(bilharzia), filariasis (including onchocerciasis, 
"river blindness"), trypanosomiasis (African sleeping 
sickness and Chagas' disease), leprosy and leishmani- 
asis. Of these diseases, malaria, schistosomiasis 
and filariasis are estimated to have at least 200 
million human victims each. In Africa alone, malaria 
(árligen?) causes about one million children's deaths annually. 
About 10 million people are infected with trypano- 
somiasis, the same number with leprosy and a slightly 
smaller number with leishmaniasis. Apart from 
leprosy, all these diseases are spread by vectors. 
In 1974, the World Health Assembly adopted a 
resolution requesting WHO to establish a programme 
for research and training in tropical diseases. 
Planning work and a pilot project conducted by a 
scientific working group were initiated simultane- 
ously. A first donors' meeting was held in October 
1975. Planning continued in an informal working 
group in which Sweden was also represented. Recom- 
mendations on the Programme's organisation and 
content, scrutinised by a special Technical Review 
Group, were presented at the next meeting, in 
December 1976, when it was decided that scientific 
activities should commence on a full scale. Certain 
questions on the administrative nature of the Pro- 
gramme were settled at a subsequent meeting in 
February 1978. The Board selected - on which Sweden 
has been continuously represented - was first 
convened in December 1978 and has met annually since. 
2.2 Objectives of the Programme 
The Programme has two mutually dependent objectives: 
- research and development to create new and improved 
methods of controlling tropical diseases; 
- reinforcement of national institutions and national 
education to raise research capability in the 
tropical countries affected by these diseases. 
According to Programme policy, the bulk of develop- 
ment work on new tools and methods must take place 
in the countries where the diseases in question are 
endemic. 
The Programme covers the six diseases mentioned in 
the introduction (2.1). It includes field studies of 
an epidemiological and operational nature, to map 
disease incidence and devise control strategies using 
new or existing methods. The Programme also funds 
socio-economic research relating to the six diseases. 
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The Programme component for strengthening the 
research capability of the developing countries gives 
long-term support to national institutions in the 
developing countries, and has thus laid the founda- 
tions for a network of research and training centres. 
2.3 Modus onerandi of the Protrrnnmip. 
The Programme is incorporated in WHO, which is its 
executive authority. WHO, UNDP and the World Bank have 
assumed special responsibility as sponsoring agencies. 
The Joint Co-ordinating Board (JOB), which meets annually, 
comprises 30 members, 12 of whom are appointed by the 
donor countries, 12 by WHO's regional offices and 3 by 
JOB. Members are appointed for three-year periods and may 
be re-elected. In addition, the three sponsoring agencies 
form a joint Standing Committee which reviews the Pro- 
gramme, has some responsibility for allocating grants 
during the financial year and submits proposals to JOB on 
general policy and financial and administrative questions. 
JCB also appoints an external Scientific and Technical 
Advisory Committee (STAC), which reports annually on the 
Programme's scientific and other activities and formulates 
criticism and proposals for changes. 
The Secretariat is located in the Geneva headquarters of 
WHO. The Director of the Programme since its inception 
has been the Nigerian Professor A. Lucas. Work is organ- 
ised in Scientific Working Groups (SWGs), each of which 
has a small Steering Committee to draw up its work plans, 
assess applications and distribute grants. In addition 
there is a working group, the Research Strengthening Group 
(RSG), which co-ordinates funding to institutions and 
education in developing countries. 
2.4 Supervision and review mechanisms of the Programme 
The central organ of control is the Scientific and Tech- 
nical Advisory Committee (STAC). Every year, this body 
reviews all the subject areas of the Programme, simultane- 
ously monitoring the Steering Committees for the various 
SWGs and the RSG; otherwise, these bodies are autonomous 
as regards planning activities and the distribution of 
funds within established financial limits. 
According to the Programme's Terms of Reference, STAC's 
15-18 members must represent medical, biomédical and other 
disciplines. WHO selects new members in consultation with 
the Standing Committee, subject to the approval of the 
annual meeting. Members are selected in a personal capac- 
ity for a three-year period, and may be re-elected. 
The task of STAC is to assess the content, orientation 
and scope of the Programme from a scientific and technical 
standpoint, to recommend priorities - including the forma- 
tion and dissolution of SWGs - and to report annually to 
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WHO and Che Standing Committee. The latter must submit a 
report containing its own and WHO*s comments well in 
advance of the annual meeting. Through smaller groups 
(Scientific and Technical Review Committees, SRTCs), STAC 
also conducts special in-depth annual reviews of certain 
subject areas. 
The Programme thus incorporates wide-ranging evaluation 
activities. An appraisal of its first five years was con- 
ducted by an External Review Committee, whose members 
included Professor Henry Danielsson of the Swedish Medical 
Research Council. With the assistance of the STRCs, the 
social and economic research component of the Programme 
was evaluated in 1983, followed by the malaria, filariasis 
and epidemiology components in 1984. The SWG on Bio- 
medical Research has recently been dismantled at the 
behest of STAC. 
STAC appears to have performed its tasks hitherto in a 
firm and independent manner. Its interdisciplinary com- 
position is not entirely convincing since, for example, 
no social scientists are included. SAREC's working group 
considers that JCB should play a more active role in the 
appointment of members of the central organs of control, 
and obtain more information on their working procedures. 
2.5 Research and development 
2.5.1 Organisation 
Activities are conducted by Scientific Working Groups 
(SWGs) and Steering Committees (SCs) as follows. 
Malaria SWG on Chemotherapy of Malaria 
(CHEMAL) 
SWG on Immunology of Malaria 
(IMMAL) 




SWG - General Research 
Three sub-groups with joint SC: 
Immunology and Basic Sciences 
Chemotherapy and Biochemistry 
Epidemiology and Snail Control 
SWG - Applied Field Research 
SWG on Filariasis 
African 
trypanosomiasis 
SWG on African Trypanosomasis 
Three sub-groups, each with its 
own SC: 
Chemotherapy and Drug Develop- 
ment (CHEMAF) 
Immunology and Pathology (IMMAF) 
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Epidemiology, Vector Biology and 
Control (EPIAF) 
Chagas* disease SWG on Chagas' disease 
Three sub-groups, each with its 
own SC: 
Chemotherapy and Parasitology 
(CHEMCHA) 
Immunology (IMMCHA) 
Epidemiology, Vector Biology and 
Control (EPICHA) 
Leishmaniasis 
Two sub-groups with joint SC: 
Chemotherapy (CHEMLEISH) 
Immunology and Biochemistry 
(IMMLEISH) 
One sub-group with its own SC: 
Epidemiology (EPILEISH) 
Leprosy SWG on Immunology of Leprosy 
(IMMLEP) 
SWG on Chemotherapy of Leprosy 
(THELEP) 
SWG on Vector Biology and Control 
SWG on Epidemiology 
SWG on Social and Economic Research 
SWG on Biomédical Research 
(dismantled at the end of 1985) 
Short descriptions of and comments on activities in 
these different spheres are given below. 
2.5.2 Malaria 
(a) Immunology 
Developing vaccines against malaria and improved 
and/or new immunodiagnostic methods has continued to 
be the main objective of immunological research on 
malaria, both within and outside the Special 
Programme. Progress to date, primarily in solving 
vaccine-related problems, has well exceeded expecta- 
tions, owing to the very rapid development of tech- 
niques used in immunology, molecular biology and 
biochemistry for identifying, characterising and 
producing the plasmodium antigens which may confer 
protective immunity. 
Vaccine development 
Research on the development of vaccines has been con- 
ducted both within and outside the Programme. None- 




results have been achieved in projects either wholly 
or partially financed, or at least initiated, by the 
Programme. This fact is important for several 
reasons, not least because it entitles Programme 
personnel to take part in negotiations concerning the 
large-scale vaccine production that must precede 
future mass-vaccination programmes. 
IMMAL therefore has close contact and collaborates 
with other international and national agencies which 
are deploying heavy resources in the field. In addi- 
tion to giving direct financial support to research 
projects, it has performed important co-ordinating 
functions, for example arranging several annual con- 
ferences at which various projects have been dis- 
cussed by researchers within and outside the Pro- 
gramme and in industry. Co-ordinating activities 
have been of prime importance for the rapid develop- 
ment of this field. Liaison has also begun with the 
pharmaceutical industry and biotechnology enter- 
prises, whose collaboration in developing and produc- 
ing vaccines is essential. Following an introductory 
conference in October 1983, regular consultations 
have been held with representatives of a number of 
companies which have shown an interest in collaborat- 
ing on vaccine development. 
Full implementation of the Programme will require 
considerable financial and personnel resources in the 
next decade. These investments are required for con- 
tinued work on gene-cloning and the characterisation 
and synthesis of antigens to combat both the asexual 
blood stages and the sexual forms of the parasite. 
In addition, major investments are needed for vaccine 
production and vaccination campaigns, including pre- 
paratory testing of vaccines, field trials and in- 
depth epidemiological studies. A major international 
conference in February 1985, at which guidelines were 
laid down for future vaccine development and the 
evaluation of vaccine trials, paved the way for the 
above-mentioned activities. Since then, there has 
been a conscious effort in the malaria component of 
the Programme to facilitate vaccine production by 
funding research in institutions where the necessary 
technology is available. Admittedly, research has 
involved massive participation by researchers and 
grant recipients, but the institutions are for the 
most part located in the industrialised countries. 
Progress to date could not have been achieved other- 
wise. While these efforts should continue for a 
further five years or so it is nonetheless also obvi- 
ous that massive resources will be needed to transfer 
the new expertise to countries where malaria is the 
outstanding health problem. This will involve, for 
example, investments in existing centres in countries 
where malaria is endemic, and the establishment of 
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new centres for clinical evaluation of vaccination 
campaigns. In this connection, the Programme has a 
unique organisational potential for making a vital 
contribution under the aegis of WHO. 
Immunodiagnosis 
Improvements in existing diagnostic testing systems 
and the development of new methods must parallel 
vaccine development. IMMAL has financed a number of 
projects yielding important results, for example the 
development of a new and highly sensitive test for 
detecting sporozoites in infected mosquitoes. Exist- 
ing radioimmunoassay and enzyme-linked immunoassay 
techniques have been improved and are partially ready 
for use in connection with vaccination trials and for 
certain epidemiological field studies. A register 
of monoclonal antibodies against the parasite's 
asexual blood stages has been started in Geneva and 
is accessible to researchers both in and outside the 
Programme. Tests for the detection of protective 
antibodies are being devised in several projects. 
Immune mechanisms and Immune pathology 
Hitherto, investigation of humoral immunity has 
predominated; research under other headings has 
therefore been overshadowed. The rapid strides of 
the vaccine programme have made it clear that better 
insight is now required into the cellular mechanisms 
conferring effective protection against the disease. 
At a conference in the autumn of 1984, attended by 
researchers in and outside the Programme, a report 
was compiled on the current situation. The Programme 
is now funding an increased number of projects 
involving investigations of, for example, cellular 
protective mechanisms and immune pathology in cere- 
bral malaria. An intensification of efforts in this 
field is planned for next few years. 
(b) Chemotherapy 
Several weapons in the battle against malaria were 
developed at the end of the 1940s, including new 
drugs such as chloroquine and insecticides such as 
DDT. Attempts to eradicate malaria were thwarted, 
however, partly by the development of resistance to 
DDT and other compounds among mosquitoes and partly 
by a rapid development of resistance to drugs in 
current use by Plasmodium falclparum. the parasite 
causing the most serious form of malaria. Although 
300,000 substances were tested for their anti- 
malarial effects in the 1970s, only a few compounds 
were produced which were conceivable for human use. 
In the field of bacteriology, by comparison, numerous 
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antibiotic derivatives were launched on the market in 
the same period. 
Mefloquine is the first compound for 30 years to 
undergo clinical trials. The drug was originally 
produced outside the Programme, by the Walter Reed 
Army Institute of Research. Fruitful co-operation 
between the manufacturer, Hoffman-La Roche, and the 
Programme has resulted in the compound now being 
registered in Switzerland for prophylaxis and treat- 
ment among certain demographic groups. Clinical 
trials (phases 1, 2 and 3) are being conducted in 
Brazil, Zambia and Thailand. Owing to the risk of o 
resistance arising, a combination anti-malarial / / 
(mefloquine, sulphadoxine and pyrimethamine) is also 
being tested in Thailand. Negotiations are also 
under way with five pharmaceutical companies on 
several new substances acting on the asexual blood 
forms (sporozoites and merozoites) . The most inter- 
; _ esting are derivatives of the Chinese drug Qinghaosu 
(artemisinine), which has a chemical structure 
entirely unlike that of anti-malarials in current 
use. Primaquine, which also acts on the tissue iforms U 
(gametes), is now the subject of intensive research, $exu,t*i 
especially into its metabolism and mechanisms of 
action. One important step forward is the success 
S) , achieved in cultivating P. vivax gametes: this now 
L makes it possible for in vitro tests to be devised to 
ascertain the effect of primaquine on the tissue 
/ stages of P. vivax. 
The Programme has actively collaborated in the 
production of test kits for in vitro trials of 
several drugs in current use against P. falcioarum. 
and tests have been standardised in multi-centre 
studies in Switzerland, Thailand and the USA. Field 
trials have taken place in several countries where 
malaria is endemic. 
Priority research fields for the immediate future 
are further clinical trials of new preparations and 
both field and laboratory studies of the development 
of resistance. Laboratory research to develop active 
anti-malarial Substances must continue, as must 
attempts to devise simple and reliable methods for 
determining drug concentrations in the blood and 
urine. 
Owing to the considerable risks of resistance to 
mefloquine appearing, a group of WHO experts have 
recommended that the drug should not be employed 
alone except to treat acutq, multi-resistant malaria, 
and that in other cases combination preparations 
should be used. 
' 
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(c) Field studies 
The Programme has supported research In the field in 
certain areas in particular: surveys of the develop- 
ment of resistance in the malaria parasite, field 
trials of drugs, chemoprophylaxis and vector control. 
A global system for surveying the emergence of 
resistance in P. falcioarum has been developed and to 
a certain extent integrated with national health-care 
programmes in parts of South-East Asia, Africa and 
Latin America. Special kits for in vitro testing of 
resistance are manufactured in the Philippines and 
distributed jointly by WHO and the Special Programme. 
Attempts to bring the pharmaceutical treatment of 
malaria into line with needs and opportunities in 
individual regions are tinder way in Central America 
(Guatemala), Africa (Kenya and Tanzania) and South- 
East Asia (Thailand). Chemoprophylactic models have 
been tested in several parts of Africa and Thailand. 
Malaria morbidity has been shown to decline sharply 
with a monthly anti-malarial intake in a controlled 
investigation in Liberia, in which Swedish research- 
ers took part, whereas in wide-ranging, uncontrolled 
programmes in Kenya and Upper Volta, for example, the 
impact was small. 
Some research on vectors has been done, and the 
research results obtained by IMMAL have also been 
useful. Our skill in identifying vectors which can 
transmit malaria to human hosts is now greatly 
improved and, using immunological techniques, it is 
possible not only to detect infection in a mosquito 
but also to identify the plasmodium species causing 
the infection. 
Surprisingly good results have been obtained in 
vector-control experiments in Somalia, using larvi- 
vorous Oreochromis fish. In one study area in north- 
em Somalia, the incidence of malaria declined signi- 
ficantly with the introduction of such fish in reser- 
voirs. The species reproduces rapidly and is also 
suitable for eating. However, the method is probably 
viable only in certain ecological conditions. Pro- 
mising trials with a special insecticide-spraying 
device have also been reported. 
Future plans primarily concern the continuation of 
ongoing epidemiological projects on treatment, 
prophylaxis, the development of resistance and vector 
control. A heavy workload for this component of the 
Special Programme may be expected, in connection with 
planned field trials of vaccines and new drugs. It 
is therefore essential for the resources available 
for field studies to be built up in malaria-endemic 
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countries, and this Includes the promotion of person- 
nel training at various levels. Close co-operation 
with the Programme components for epidemiology, 
social and economic research and resource build-up, 
as well as with other components in the field of 
malaria, appears to be an essential precondition of 
success. 
2.5.3 Schistosomiasis 
Of the diseases covered by the Programme, schisto- 
somiasis (bilharzia) is that which, after malaria, is 
considered most serious from the world health stand- 
point. The disease is caused by a worm (schistosoma) h zJ, 
and is widespread in tropical and subtropical regions 
of South America, Africa_ and Asia. The number ofj (k^<L u^-ce^: 
individuals currently infected is estimated at 200 to * 
300 million. Since the disease spreads via infected 
water, children are particularly susceptible; about 
90 per cent of infections are probably acquired by 
the age of 10 or 15. 
Three species of Schistosoma are pathogenic to 
humans. Where geographical incidence and localisa- 
tion in the infected organism are concerned, they are 
mutually distinct: S. mansoni (South America and 
Africa) is localised in the blood vessels in the 
portal system, while S. haematobium (with the same 
geographical distribution) inhabits the blood vessels 
surrounding the bladder. S. 1aoonicum is restricted 
to Asia, including the Philippines, and localised in 
certain blood vessels connected to the intestinal 
f '"•■Ci canal7 S. mekongii and S. intercalation are two other 
r* '-oc species with a relatively small geographical range. 
One phase in the parasite's reproduction is the 
formation and excretion of eggs via the infected 
individual's faeces or urine. Dead eggs deposited in 
the tissues during the excretion phase give rise to a 
chronic inflammation which, if sufficiently pro- 
longed, leads to the transformation of connective 
tissue in the tissue in question (intestinal or blad- 
der wall, liver or spleen), with resulting functional 
defects. The disease thus tends to be chronic, and 
its major significance as a world health problem lies 
in the enormous number of infected individuals, whose 
work capacity is diminished. However, schistosomi- 
asis not infrequently takes an acute, more serious 
course, and may be fatal; according to estimates, it 
causes about 750,000 deaths annually. 
Effective chemotherapy has gradually become avail- 
able in recent years. The advantage of effective 
drugs such as oxamniquine (for S.mansoni) and metri- 
phonate (for S. haemotobium) is that they are relat- 
ively cheap, while one drawback is that doses often 
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need to be repeated. Praziquantel, one of the latest 
drugs to appear, Is effective in a single dose 
against both S. mansoni and S. haemotobium. but is 
about 5-8 times more expensive and therefore imprac- 
ticable for widespread use in countries with hard- 
pressed economies. It may briefly be mentioned that 
the intricate interplay between the parasite and the 
infected host organism is one reason why an effective 
vaccine has been so elusive. In experiments on 
animals, a protective effect has been attainable from 
cy, . "certain types of vaccine, but there is no current 
likelihood of a vaccine for human use being produced 
in the near future. 
The Programme's efforts in research on schistosomi- 
asis have, in short, concentrated on "identifying and 
developing new scientific methods for more effective, 
cheaper and simpler disease control". Control 
measures may in theory be oriented towards both para- 
site stages in the intermediate host - various fresh- 
water snail species - and stages in the definitive, 
human host. 
The efficacy of chemicals against snails has been 
investigated in projects funded by the Programme. 
Positive effects have been achieved where use is 
limited to relatively small, well-defined areas. Any 
large-scale use of molluscicides requires thorough 
evaluation and, above all, consideration of possible 
ecological side-effects. The potential of mollusci- 
cides of plant origin (such as Endod) is particularly 
interesting in this context, since such preparations 
can often be made from plants cultivated locally. 
However, molluscicides used as the sole means of 
intervention have had discouraging results where 
transmission is concerned. 
To provide documentation for various health-care 
programmes, reliable, simple and cheap epidemiolog- 
ical methods are required to establish the range and 
prevalence of infection. With the support of the 
Programme, a simple and sensitive parasitological 
method has recently been developed for detecting eggs 
in the urine (S. haematobium). Since almost all 
children with massive S. haematobium infections have 
blood in their urine, the development of cheap test 
strips for haematuria detection is also being pro- 
moted. For the diagnosis of S. mansoni. its eggs 
must be detected in the faeces - a method which is 
arduous and time-consuming, and requires considerable 
experience on the part of laboratory staff. As an 
alternative to parasitological methods,serological 
methods have been developed. Their weakness, how- 
ever, is that in their present form they cannot 
distinguish between active infections, i.e. those 
requiring treatment, and those which have healed. 
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Intenslve research has been conducted, largely on 
Programme funds, to expose the mosaic of antigens In 
the various stages of the parasite's life cycle, In 
order If possible to find one or more "diagnostic 
antigens" which may permit a differentiation of the 
various stages of Infection. The production of mono- 
clonal antibodies, which may be used to engender 
these diagnostic antigens in pure form, is also of 
outstanding current interest. The Programme has also 
funded the development of simplified serological test 
methods. 
The combination of a suitable diagnostic antigen 
with a cheap and simple serological technique may 
bring enhanced opportunities of large-scale epidemi- 
ological field studies which, in turn, can pave the 
way for further attempts at control, with correct and 
specific orientation. 
The Programme has also co-operated in developing 
and studying various pharmaceuticals for the treat- 
ment of schistosomiasis; one example is the phase III 
studies of Praziquantel at the Tropical Research 
Centre in Ndola, Zambia. Large-scale chemotherapy 
has recently been applied in conjunction with the 
field projects in Burundi and Zanzibar. Initially, a 
striking reduction in the incidence of infection was 
noted. Since the studies conducted in other areas 
showed that a large segment of a treated population 
become reinfected relatively quickly, researchers 
prefer to await another evaluation before attempting 
to assess how long the effects of mass chemotherapy 
alone can last. Geographical and cultural diverg- 
ences between different areas appear to play a major 
role in this connection. It should be emphasised 
that, for an optimal transmission-inhibiting effect, 
chemotherapy must be employed in conjunction with 
other measures such as the use of molluscicides, 
construction of latrines, removal of vegetation from 
beaches used for bathing and fishing, instruction on 
the spread of infection, etc. In this context, it is 
also worth mentioning that the Programme has initi- 
ated and stimulated research into the biochemistry 
and metabolism of the parasite, with a view to 
developing new, specific and selective anti-parasite 
compounds. The schistosomasis component of the Pro- 
gramme also offers numerous examples of fruitful co- 
operation between institutions in developing and 
industrialised countries. 
In summary, 
crucial for, the expansion of knowledge of this dis- 
ease in recent years. As in other areas, the picture 
is one of contracting economic frames in an expansive 
development phase. It may also be pointed out that 
schistosomiasis 
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prevlous major sponsors, such as the Edna McConnell 
Clark Foundation, have drastically cut their 
contributions to schistosomiasis, in favour of other 
fields. This being so, a concerted effort is 
essential to retain, or if possible reinforce, the 
role of the Programme in such research. 
2.5.4 Filariasis 
This group of diseases includes several infections 
caused by worms of the genus Filaría. 
The two most important and commonest filarial 
diseases in human medicine are: 
1. Onchocerciasis. This disease is most common in 
tropical Africa, but it also occurs in the 
eastern Mediterranean region and parts of Latin 
America. About 40 million people are estimated 
to have the disease. The infection is trans- 
mitted by black fly (genus Simulium), which 
contains the larva of Onchocerca volvulus. In 
humans, the adult worms collect in subcutaneous 
nodes or swellings. The symptoms of the disease 
are caused by the larvae - microfilaria - enter- 
ing the blood stream. Victims suffer from 
intense itching and ocular symptoms, owing to the 
larvae damaging various parts of the eye. 
Onchocerciasis often leads to blindness. In 
endemic areas, blindness is therefore common in 
the adult population. 
2. Lymphatic filariasis. This disease occurs in 
Asia, Africa and South America. It is estimated 
that about 90 million people are Infested with 
lymphatic filariasis, which can be caused by 
three different species of parasite. The adult 
worms infest the lymph vessels and the micro- 
filaria inhabit the blood stream. The disease 
manifests itself at an early stage as chronic 
swellings, above all in the lower extremities. 
The Programme's efforts to combat filariasis have 
been concentrated primarily in two areas: the devel- 
opment and screening of filaricides, and immunology. 
No satisfactory drug has yet been found against any 
of the filariases. Researchers are currently seeking 
a safe, non-toxic anti-filarial compound which can 
attack the macrofilaria or function embryostatically. 
Microfilaricides are transitory in effect; moreover, 
the majority produce severe side-effects in the form 
of the "Mazotti reaction", owing to toxic and allerg- 
enic substances released when the microfilaria 
disintegrate. 
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One problem connected with the drug trials has been 
that of finding suitable animal ajubj gets : The 
Filarla species which attack humans cannot infest 
animals, and work must therefore involve closely 
related Filarla species in experimental animals. An 
adequate animal model for Onchocerca species has now 
been found: cattle in Australia, after infection with 
0. gibsoni. exhibit symptoms closely resembling human 
onchocerciasis. However, owing to the animals' size, 
the model is not ideal. 
Several thousand substances have been tested in 
experiments on animals, and two are now virtually 
ready for human trials. Ivermectin is a new anti- 
filarial compound now undergoing tests on humans, and 
it has yielded promising results. The compound 
affects adult female filarla, causing the larvae they 
bear to die. Only in exceptional cases does the 
Mazotti reaction occur. 
There are close links between the Special Programme 
and the Onchocerciasis Control Programme in the Volta 
River Basin in West Africa. Collaboration consists 
of testing new filaricides and joint vector-control 
efforts. 
In addition, the Programme supports research cap- 
able of elucidating immune reactions of importance 
for pathogenesis in natural infection or for drug 
reactions. Other activities conducted under Pro- 
gramme auspices are surveys aimed at exposing the 
antigen mosaic, and the design of simple, specific 
immunodiagnostic tests. The latter activity has 
been beset by problems owing to the occurrence in the 
Filaría parasites of antigens shared by, or cross- 
/-/ s-H j réactif with, antigens from other parasites. How- 
ever, researchers have recently succeeded in develop- 
ing specific methods of detecting filarial antigens 
in the blood stream, and an attempt is now being made 
to simplify these methods so that they are practic- 
able in endemic areas. 
2.5.5 Trypanosomiasis 
Trypanosomiasis is an umbrella term for several dis- 
eases caused by flagellata belonging to the same 
family, but otherwise not very closely related. The 
diseases vary pathogenetically and clinically, and 
occur in different continents. African sleeping 
sickness occurs only in Africa south of the Sahara, 
and Chagas' disease is confined to the Americas, 
chiefly South and Central America. 
African sleeping sickness 
The disease is transmitted by the bite of the tsetse 
fly. The parasites first proliferate around the bite 
SAREC -16- 
and then spread to the nearest lymph-gland site. 
Reproduction proceeds apace, mainly In the lymph and 
blood, and the parasites are transported to all 
organs of the body. Parasitic infestation of the 
blood follows an undulating pattern: each peak 
corresponds to the appearance of a new surface anti- 
gen borne by the parasite. The central nervous 
system is invariably affected, and in the absence of 
treatment the disease culminates, as a rule, in death 
from chronic encephalitis. 
There are two types of sleeping sickness in Africa. 
In East Africa, Trvpanosoma rhodesiense causes a sub- 
acute infection, which may be fatal within a few 
weeks or months, whereas T. gamblense in West Africa 
gives a sub-chronic or chronic infection which 
usually lasts for several years. 
Trypanosomiasis in Africa also poses a severe prob- 
lem in veterinary medicine. The infection occurs in 
livestock and game, and may cause serious food-supply 
problems. 
Around five million people in Africa inhabit 
endemic regions, and the known incidence is 20,000 
cases annually. However, the true morbidity figure 
is probably a good deal higher. 
The Special Programme has provided considerable 
financial support to research on sleeping sickness, 
but its most important contribution has been in 
drawing attention to this intractable - and, at the 
same time, scientifically interesting - disease, and 
co-ordinating research and trypanocide distribution. 
Some of the most significant scientific results 
stem from research conducted outside the Programme. 
The identification and investigation of variant 
antigens borne by the parasite was first conducted 
outside the Programme and later received Programme 
support, though to a limited extent. Production of 
monoclonal antibodies, like the design of techniques 
for in vitro cultivation, previously took place 
entirely outside the Programme at ILRAD (the Inter- 
national Laboratory for Research on Animal Diseases) 
in Nairobi. 
A few examples of Programme efforts in research and 
disease control are given below. 
Under Programme auspices, a network of research 
groups working on various aspects of African sleeping 
sickness has been formed. Epidemiological work 
funded by the Programme is being carried out in 
several locations in Africa. Researchers are 
attempting to map the incidence and extent of the 
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disease. Related studies aimed at identifying vector 
species in the tsetse complex are under way. Simple 
aids have also been produced or developed and dis- 
tributed by the Programme: examples are a simple 
agglutination test for the detection of antibodies in 
? T. eambiense infection, a miniature anion exchanger 
which concentrates parasites in the blood (to deter- 
mine parasitaemia) for T. rhodesiense diagnosis, and 
simple tsetse traps which, impregnated with insecti- 
cides and odoriferous substances resembling the host 
animal's smell, are highly effective. 
The Programme supports the development and screen- 
ing of trypanocides, and drug trials are conducted, 
for example, at a Programme-funded centre in Ivory 
Coast. The Programme has also initiated and funds 
post-mortem studies of sleeping-sickness victims. 
Investigations of this kind take place in Ivory Coast 
in collaboration with Glasgow University, and have 
yielded valuable information on the pathogènesis of 
the disease. 
2.5.6 Chagas' disease 
Chagas' disease is a chronic infection caused by T. 
cruzi. transmitted by blood-sucking triatomine bugs 
whose preferred habitat is poorly constructed and 
maintained dwellings. The infection thus has a 
clearly social background. Its onset is usually 
acute, with general symptoms of infection, and its 
subsequent course is subclinical, for a variable 
length of time - sometimes up to several decades. 
The manifest, chronic stage is characterised by irre- 
versible changes in the peripheral nervous system, 
heart, oesophagus and large intestine. Patients 
often die of heart failure. The disease may be cured 
in the acute phase, but there is no effective therapy 
for the chronic phase. 
__ In previous years, the Programme's Chagas1 disease 
ikjL component] failed to function satisfactorily, and 
difficulties were experienced in co-ordinating 
research, which was not always l^target-oriented. — V€^-- 
Since the Steering Committees were reorganised - they 
now chiefly comprise researchers from endemic 
countries - activities have developed extremely well. 
Attempts have been made to co-ordinate existing 
resources by forming research-group networks. 
Activities have been primarily oriented towards 
mapping the incidence and extent_of the disease in - 
Latin America. Research groups in various endemic 
countries are now collaborating and carrying out 
parallel studies, using standardised protocols and 
methodology. Both prevalence studies and longitud- 
inal projects are being conducted in this manner. 
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Ten diagnostic laboratories in Latin America and one 
in the USA (CDC) co-operate and exchange information. 
One of the South American laboratories serves as a 
reference laboratory. The Programme is also funding 
current efforts to prevent transmission via blood 
tranfusion and to control vectors by new insecticides 
and new methods of using them, for example incorpor- 
ating them into indoor paint for dwellings. Finally, 
the Programme is funding ongoing efforts to produce 
and screen new drugs against Chagas1 disease. 
It should be pointed out that Chagas' disease 
receives considerably less financial support from the 
Programme than African sleeping sickness, although 
the former is at least as serious as and probably 
more prevalent than the latter, and although consid- 
erably less support for research on Chagas1 disease 
comes from sources outside the Programme than for its 
immunologically more interesting African counterpart. 
2.5.7 Leishmaniases 
The leishmaniases are a group of diseases, all caused 
by species of the large Leishmania family. Infection 
is transmitted by sandflies. In the vector, the 
parasite is a thin, elongated flagellatum; in its 
warm-blooded host, it soon metamorphoses) into a 
small, oval parasite /Inhabiting1 phagocytic cells, t-j 
especially macrophages. ^ 
Leishmaniasis occurs in the Mediterranean region 
and large parts of Asia (particularly India), Africa 
and South and Central America. The disease may mani- 
fest itself as a general infection (visceral leish- 
maniasis, VL), with fever, anaemia and invasion of 
the liver and spleen. Untreated, VL is almost always 
fatal. Leishmaniasis may also appear as localised 
ulcers or lesions in the skin and/or mucous mem- 
branes. As in leprosy, the interaction ¡of the 
„ parasite and the host's immune system may produce a 
gamut of symptoms, from a state characterised by 
i virtually defunct cell-mediated immune defences and 
heavy infestation to a condition of excessive cell- 
bound immunity in which parasites are sparse. 
Neither of these extreme forms heal spontaneously. 
On the other hand there are self-healing, relatively 
benign forms halfway along the scale. Systematically 
and immunologically, the Leishmania species of the 
Old and New Worlds are related only distantly. 
As with Chagas' disease, the leishmaniasis compon- 
ent of the Programme receives very restricted finan- 
cial support. Nevertheless, the Programme has made 
substantial contributions to leishmaniasis research, 
particularly in the vital classification of infective 
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agents. Modern methods, such as isoenzym^&i^ deter- hj <£. 
mlnatlon, monoclonal antibodies and hybrid DNA tech- 
nology, have been developed for the characterisation 
of species and strains. The establishment of refer- 
ence centres in Europe, Asia and Central America is Q 
significant: these centres can classify strains/inr/ ^ ^ 
/irsulatlotv from patients, which permits the incidence H o ¿ a, 
and range of various species to be surveyed. Indivi- 
dual laboratories can also concentrate on particular 
parasite strains. In addition, a serum bank is 
expected to be created shortly, and will]be able to 
provide laboratories with reference sera. These 
measures will greatly facilitate research and 
development work at regional level. 
The Programme is also carrying out important work 
in the vector-control research field, and has initi- 
ated and funded investigations of infective agenté ^ 
reservoirs. In spite of limited resources, drug 
research in the field is also receiving support. 
2.5.8 Leprosy 
Leprosy cases now number about 11 million worldwide, 
concentrated in Africa, Asia and South America. In 
Europe there are about 25,000 cases. The disease is 
caused by Mvcobacterium lenrae. which is related to 
the tuberculosis bacterium and gives rise to a 
chronic infection. Owing partly to the infected 
individual's lowered resistance to /disease^ there is H 
a broad spectrum of symptoms from a harmless, local- 
ised skin infection to one which has spread to 
several organ systems. In the latter case, the 
patient suffers serious damage to the peripheral 
nerves and skin in particular, which may lead to 
severe disablement. The disease is also problematic 
in that it has immense psychosocial consequences, 
often culminating in the individual's ostracism from 
society. 
The Programme's leprosy research has focused both 
on immunology (IMMLEP) and on chemotherapy (THELEP). 
Immunological research has included the following 
emphases : 
(1) The development of sensitive and effective 
diagnostic methods to permit early diagnosis and 
the commencement of treatment at an early phase 
of the disease. Thus it has been possible to 
characterise and synthesise a diagnostic antigen 
(PGL-1), against which leprosy patients alone 
appear to have antibodies. Monoclonal anti- 
bodies are also being studied for use in 
immunodiagnostic methods. 
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(2) The development of an effective vaccine. This 
has involved particular difficulties, since 
leprosy bacteria cannot be cultivated in the 
conventional way. Vaccine development is still Ç 
dependent on the production of /thë_xaw material /""V 
from infected armadillos. Preliminary trials 
have shown that the vaccine is tolerated 
sufficiently well to permit large-scale field 
trials, and such trials have already started or 
are planned in India, Venezuela and Malawi. In 
connection with the WHO vaccine development pro- 
gramme, molecular-biological research is also 
being funded, to characterise and isolate pro- 
tective antigens with the aid of hybrid-DNA 
technology for use in future vaccines. IMMLEP 
plays an important part in co-ordinating these 
research activities. 
Under the auspices of THELEP, research is being 
conducted into the development of resistance in 
leprosy bacteria to drugs such as dapsone, a sulpha 
compound which has hitherto been the main form of 
treatment. Owing to dapsone resistance, the poten- 
tial use of this drug is not as simple as it was 
^ formerly, and further agents of leprosy control are 
needed. Several projects are in progress or planned, 
for example in Mali and Malawi, to evaluate the 
effects of various drug combinations; such combina- 
tions have already yielded promising preliminary 
results in India. In another project in the 
Philippines, researchers are studying possible ways 
of using prothionamide without this drug giving rise 
ytf to hepatic toxicity. 
The chief importance of the leprosy component of 
the Special Programme lies in its information and 
liaison work, not least in promoting contacts between 
developing and industrialised countries and organis- 
ing the exchange of material between researchers in 
the field. In the development phase the component 
has now entered, it appears particularly important 
for support to be maintained. 
2.5.9 Epidemiology 
Since its inception, the Programme has had an auto- 
nomous epidemiological component, with overall 
functions for all the diseases, to collaborate with 
the groups for individual diseases. 
Epidemiological studies have been in progress in 
a number of areas where several of the six diseases 
occur simultaneously, such as Ndola, Zambia. These 
have permitted endemic-area surveys of disease incid- 
ence which, in turn, are valuable for the planning 
and implementation of future control programmes. 
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Analytical epidemiological methods may be used for 
investigation of the relations between infections and 
disease, and in studying effects of individual- 
related and environmental and/or hygienic factors. 
Advances in epidemiological methodology have 
enabled surveys to be conducted more rapidly and 
efficiently than ever. Case-control studies have 
proved to be an important aid in the identification 
of risk factors, and also in assessing the impact of 
intervention procedures adopted. It has been poss- 
ible for primary health care to utilise the simple 
epidemiological methods developed for diagnostics and— 
the monitoring of disease. Further development of 
such methods should be feasible - for example, 
methods of measuring the incidence and prevalence of 
infections in areas of high demographic mobility. 
The following measures are planned for the immedi- 
ate future: 
- Attempts to identify factors of potential signi- 
ficance for the courses, of the six diseases. 
- Cost-effectiveness studies of possible control 
programmes, taking into account the health problems 
posed by the infection concerned in an endemic 
area. This type of assessment is essential for the 
optimal allocation of available finance. 
- Evaluation of current control programmes as a basis 
for future operational research. 
It is vital for national and regional capacity to 
be strengthened in the epidemiological field. Educa- 
tional programmes comprising both postgraduate 
courses and research studies for more advanced 
researchers from endemic countries, as well as work- 
shops in epidemiological research methods, are there- 
fore planned. 
The epidemiological component of the Programme 
initially encountered certain difficulties in finding 
suitable projects to support. Its goals were revised 
in 1984, and the advisory scientific group was 
reorganised. It now co-operates both with the social 
and economic research component of the Programme and 
with other WHO programmes, and appears to be 
functioning well. During 1985, the Programme's STAC 
group will be devoting one of its recurrent reviews 
to this component. 
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2.5.10 Social and economic research 
When the Special Programme was Initiated, the consen- 
sus vas that research on medical technology must be 
supplemented by research on the adaptation of this 
technology and efforts to get it accepted in develop- 
ing countries. Programme policy in relation to the 
social sciences was revised in 1981. More attention 
began to be paid to social, cultural and economic 
factors in the spread and control of diseases; in 
addition, the importance of epidemiology as a tool 
for assessing the prevalence and incidence of various 
diseases was strongly emphasised. 
Only researchers in developing countries obtain 
Programme grants for social and economic research. 
The Programme is now funding descriptive and analy- 
tical research within the broad fields of social 
science, sociology, social anthropology, history and 
economics (e.g. cost assessments of adopting various 
disease-control strategies and developing different 
types of models). Some of these areas still need 
methodological improvement before their findings can 
be used in the Programme. Moreover, the component 
has an important role in field trials of various 
compounds. 
The number of projects with social and economic 
aspects has been heavily increased in recent years, 
and 57 projects are now under way. As the 
Programme's social scientists see it, interest is 
growing among the researchers involved in control of 
the specific diseases. Each disease-oriented group 
has attempted to review the most promising control 
measures, and migration, for example, was found to be 
one of the factors influencing the spread of infec- 
tions. Popular migrations affect the immunity situ- 
ation in populations as a whole. Different groups' 
attitudes towards the diseases and towards methods of 
prevention and care play a major part in the success- 
ful implementation of control programmes. Popular 
participation in designing such programmes has often 
been neglected to date, and information programmes 
have not preceded start-ups. The Special Programme 
supports projects in these fields, and also studies . 
to elucidate the integration of disease - contror pro - 
grammes with primary health care. The role of women 
in the prevention, diagnosis and control of tropical 
diseases, for example, has been underestimated in 
many health-care programmes. 
One important issue is the recruitment of research- 
ers from developing countries to work on interdis- 
ciplinary projects. Hitherto, Programme funding of 
such training has been limited, but possible -M.Sc. ^ 
courses in fields such as the social sciences and 
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public health are being investigated. One problem is 
career structure: in many developing countries, 
attractive promotion prospects are needed to tempt 
young researchers into these fields. 
From the start, the Programme had set aside funds 
for two people to study the social and economic 
aspects of disease, but only one - an economist - had 
been appointed. For one year, a social anthropolog- 
ist financed by Danida had assisted the Programme. 
The programme of social and economic research on 
tropical diseases is of impressive quality, in view 
of the Special Programme's scarce personnel 
resources. The Programme has also prompted other WHO 
programmes to intensify their efforts in the social 
sciences. 
It seems vital to point out the need for represent- 
atives of social sciences other than economics, not 
only among Programme staff but also in STAC and other _ , 
groups. The current researcher in chargej is anj ^ ^ 
economist but has succeeded admirably in acquiring 
familiarity with other social sciences as well. 
2.5.11 Vector biology 
(see App. 9) 
2.6 The balance between basic and applied research and between 
research based in industrialised and developing countries 
The Special Programme supports a limited amount of 
basic research. It is above all in immunology, and 
especially the malaria and leprosy components, that 
it funds projects in the nature of fundamental 
research. An estimated 50 per cent or thereabouts of 
research grants disbursed in the immunology sub- 
components and 20-30 per cent of those in the chemo- _ 
therapy sub-components are earmarked for basic 
research. The remainder are for applied research, 
but mainly in the laboratory sector. In connection 
with development work on vaccines against leprosy and 
malaria, experiments at molecular level are required, 
and the same applies to the development of modern 
techniques for identifying and typing several of the 
infective agents in question. The rapid development 
of biotechnology has greatly benefited the Programme. 
It may be said that the Programme's funding of basic 
research is well balanced against its aim of produc- 
ing agents for controlling the six target diseases. 
Table 1 shows the distribution, by country or con- 
tinent, of research grants for immunology and chemo- 
therapy in the specific disease-oriented components. 
The overwhelming proportion of grants have gone to 
the USA and a somewhat smaller proportion to Europe: 
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naturally, the grants go to institutions with the 
largest resources, and the majority of well-developed 
laboratories with the potential for high-tech 
research are in Europe and the USA. In Australia, 
highly skilled research on several of the target dis- 
eases has been built up, and an enhanced Programme 
commitment in this country should be considered. 
Another question is whether more use should not be 
made of the laboratory research expertise in several 
Programme-funded institutions in endemic areas, 
particularly South-East Asia and Latin America. 
Table 2 shows the distribution of Programme grants 
among disease-oriented components and countries or 
continents. As mentioned above, most laboratory 
research grants go to the USA, and somewhat fewer to 
Europe; among European countries, Britain receives 
most. Other parts of the world obtain consistently 
few grants for laboratory research, except for 
Chagas' disease, on which most research takes place 
in Latin America. However, it is somewhat surprising 
that six Chagas' disease projects are under way in 
Europe, and also that eleven grants for research on 
African sleeping sickness go to the USA. Sleeping- 
sickness research is otherwise largely concentrated 
in Africa, with European scientific support. 
Research grants for field studies of the six target 
diseases have to a greater extent been disbursed in 
endemic countries, although 30 per cent have still 
gone to non-endemic countries. 
As shown in Tables 2 and 3, the malaria component 
has the biggest share of the Programme's research 
grants for the specific disease programmes. This can 
be justified with reference to the extent and sever- 
ity of malaria, as well as existing opportunities of 
producing an effective vaccine in the foreseeable 
future. These considerations, coupled with the fact 
that malaria can infect Vestem visitors, also 
enhance prospects of obtaining grants from funding 
research councils and institutions in industrialised 
countries. Such opportunities are hardly at the 
disposal of the disease components for Chagas' dis- 
ease and leishmaniasis, which are only meagrely 
funded by the Programme. A certain redisposition of 
available research funds to the advantage of these 
two components should therefore be considered. 
Nevertheless, it is clear that the major field 
trials planned for the evaluation of new vaccines 
against leprosy and malaria, as for new drugs, will 
not easily find grant donors outside the Programme, 
and that the Programme will therefore face major 
financial problems in the next few years. 
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2.7 The strengthening of research capability as a component of 
the Programme 
Within the Programme, there is ample awareness of the 
problems which may arise in connection with attempts 
to build up or reinforce research capability in 
developing countries. Political instability may make 
activity in the study area difficult or even imposs- 
ible. The Programme therefore often adopts a wait- 
and-see attitude when it comes to supporting institu- 
tions in countries where the political situation is 
unstable. A country should also be sufficiently 
developed economically to take over the costs of 
expanded research activities when the Programme grant 
period expires after 3-5 years. For funding 
purposes, the Programme as a rule stipulates a 
university organisation of fairly high standard, with 
good relations between the university, ministry of 
health and national health programmes. The Programme 
has also tried to obviate cultural and social 
problems by appointing experienced researchers 
(university professors) from each of the three 
disease-endemic regions (Africa, South-East Asia and 
Latin America) to work in the respective region. 
They all possess good local knowledge and often visit 
the institutions in their own areas. 
Attempting to improve research capability in a 
country which has had a well-developed organisation 
led and administered by foreign researchers involves 
particular problems. In many countries, researchers 
have left their posts without rooting their activit- 
ies in the localities concerned, to the extent which 
is desirable, by forming a national cadre of 
researchers. The results of much essential research 
on the endemic diseases of the developing countries 
are now to be found in the industrial countries' 
libraries. It is vital that past errors of this kind 
are not repeated. 
About 25 per cent of the Programme budget goes on 
the component for strengthening the research capabil- 
ity of developing countries. Of this sum, half is 
used for institutional support, in the form of either 
capital grants or long-term institutional grants. 
The remainder is used for training. Research stud- 
ents, and in some cases institutional technicians, 
can obtain scholarships to study at other institu- 
tions. The Programme is increasingly trying to pro- 
mote institutional training in other endemic coun- 
tries, but the majority of research students are 
still sent to the West. On returning to the home 
institution, a young researcher may receive a re- 
entry grant to start his or her own research. 
Educational support is always given after application 
by the research student's institution, never to a 
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private applicant. The Programme continues to dis- 
burse grants to institutions it already supports, and 
sometimes tries to expand this activity with the help 
of other, smaller institutions in the same regions. 
Owing to limited financial resources, initiating new 
projects is feasible only to a small extent. 
The Programme also includes other capacity- 
strengthening activities. Some training of 
researchers is built into the specific disease 
components; these tend to award research grants to 
groups receiving research students from endemic 
countries. Some courses are also held in conjunction 
with other Programme activities: the components for 
social and economic research and epidemiology, for 
example, have arranged their own seminars and 
workshops independently. The aim is for the 
component for strengthening research capability to 
take over responsibility in future for the 
educational activities now pursued by the biomédical 
sciences group. 
The Programme is trying to create a network of 
groups involved in providing scientific information 
in the regions. In addition, grants to institutions 
always cover subscriptions to scientific journals. 
The institution must bind itself to retain the sub- 
scription even after the funding has ceased. Even 
so, many libraries in developing countries almost 
entirely lack journals and other scientific literat- 
ure from the last few years, owing to the current 
economic crisis, especially in the African countries. 
The Programme is attempting to establish collabora- 
tion between the research institutions it supports 
and other institutions in the same regions with 
experience in the same research fields. This 
approach seems to have been particularly successful 
in South-East Asia, where there are now networks of 
co-operating institutions which can jointly tackle 
current issues on a broad base. 
In connection with its capability-strengthening 
activities at various institutions in the developing 
countries, the Programme also collaborates with 
institutions in the industrialised countries, especi- 
ally universities and tropical research institutes in 
Britain and the USA. Of a total of 36 institutions 
in developing countries which have received Programme 
support since 1983, nine are also supported by 
Britain and 13 by the USA. The Programme also col- 
laborates with- Sweden, via SAREC, and up to 1984 took 
part in organising a research training programme at 
the University of Ibadan, Nigeria, with the Depart- 
ment of Clinical Pharmacology, Karolinska Institute. 
Three physicians and a microbiologist from the Somali 
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National University are currently being trained at 
the Department of Parasitology of Sweden's National 
Bacteriological Laboratory. Activities of this kind 
constitute much-needed backing, both financial and 
scientific, for institutions in developing countries. 
However, there also seems to be a certain inherent 
future risk. Research groups from industrial coun- 
tries who have formerly participated in research 
programmes in endemic countries, above all in Africa, 
without giving their activities firm roots in the 
respective institutions there, are now once more 
involved in co-operation with developing countries. 
One can but hope that the Programme will ensure that, 
this time, the co-operation will be of lasting value 
to the local institutions concerned. (Table 4). 
Efforts to build up research capability in endemic 
countries are aimed at making meaningful research 
possible at various levels in areas where one or more 
of the six target diseases are endemic. Political, 
economic and cultural factors may greatly impede such 
attempts. The Programme appears to have achieved 
most success with its resource-strengthening activi- 
ties in South-East Asia, where preconditions have 
also been most favourable. This region now has local 
research groups of a high standard, fully comparable 
with groups in the West. The Programme's activities 
in Latin America have also been successful. The most 
daunting problems have been those in Africa, where 
dependence on the institutions and researchers of 
industrial countries is still heavy and the future of 
even well-established institutions, such as the one 
at Ndola, Zambia, must be regarded as uncertain. 
2.8 Collaboration with the pharmaceutical industry 
2.8.1 Introduction 
Major problems are involved in developing new drugs 
to treat parasitic tropical diseases. In general, 
such research and development work is costly: meflo- 
quine - an anti-malarial compound • is estimated to 
have cost MSEK 1,000 to develop. It is a protracted 
business. Research is often more speculative in 
nature than for other diseases, i.e. relatively fewer 
? preparations prove to be effective. Complex para- 
sitie life cycles, the appearance of resistance- to 
drugs, deficient background data (owing to previous 
neglect of these areas) and a lack of satisfactory in 
vitro and in vivo models are examples of other diffi- 
culties. Treatments must be simple (often single 
doses) and drugs cheap in order to be of practical 
importance in developing countries. The presumptive 
incomes of the pharmaceutical industry are therefore 
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small, for numerous reasons. According to one estim- 
ate, the world market for anti-parasite compounds is 
MSEK 30, whereas that for antibiotics is MSEK 3,000. 
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2.8.2 Collaboration with the industry 
Collaboration with the pharmaceutical industry has 
grown considerably: the Programme considers this 
essential for the development, testing, manufacture 
and marketing of new compounds. Types of liaison 
vary. The Programme employs WHO model agreements. 
In developing drugs, informal co-operation is the 
rule. One example is the anti-malarial compound 
mefloquine, where the Walter Reed Army Institute, 
USA, the Special Programme and the Swiss pharma- 
ceutical company Hoffman-La Roche co-operate in 
development and production. In addition, a compound 
for treating onchocerciasis has been developed and 
tested clinically by the firm Merck & Company Inc., 
USA, the Special Programme and the WHO programme for 
control of this disease. Thirty-seven industrial 
agreements have been concluded with enterprises in 
seven different countries, the overwhelming propor- 
tion in the USA. In 1985, co-operation was in pro- 
gress with 20 companies. WHO has patent rights, and 
works generally to promote the interests of develop- 
ing countries within the framework of industrial 
collaboration. 
In brief, the Programme has a realistic attitude 
towards the need to collaborate with industry. The 
agreement with Hoffman-La Roche is considered to be a 
model of satisfactory collaboration of this kind. 
2.9 Reports on th» Prnfrrnnrn.» 
Prior to the annual meetings, the Special Programme 
issues both a comprehensive annual report describing 
activities in the different occupational spheres and 
a catalogue giving systematic accounts of grant 
allocation in the various Programme fields. The 
contents of the former were previously issued in a 
manner which made overview awkward, and delegates to 
annual meetings therefore found it difficult to 
obtain a clear picture of activities. Moreover, 
reports omitted to state whether the various projects 
were financed entirely or partially by the Programme. 
The latest annual report - for the financial years 
1983 and 1984 - is much clearer and more satisfactory 
where both content and layout are concerned. It pre- 
sents an overview of the most important research 
findings in the various fields and a clear account 
both of Programme grants and of results and publica- 
tions unconnected with the Programme. This change in 
Programme reporting corresponds to the desire for 
clearer presentation expressed in SAREC's 1981 evalu- 
ation report. 
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In addition, the Programme includes extensive 
publication activities - newsletter, bibliographies, 
etc. - and reports from SWG meetings and seminars are 
also available. One valuable series of publications 
contains lectures and comments from all Programme 
workshops. However, it would also be useful for 
donors wishing to obtain a thorough knowledge of the 
Programme to have access to Scientific and Technical 
Review Committees' reports, which are at present 
confidential. 
2.10 Funds and budget of the Programme 
Trends in Programme income and expenditure are shown 
in the diagram below, which is taken from the 1983/84 
annual report. 
Figure 1 
To date, the Programme has obtained contributions 
from over 40 countries and organisations. Alto- 
gether, the largest amounts have been donated by 
Denmark, the USA (support was first given in 1979) 
and Sweden. Since 1981, the World Bank grant has 
corresponded to about 10 per cent of its budget. 
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Total Programme expenditure in 1983 was slightly over 
US $ 20 million. (Figure 2). 
In the initial years of the Programme, Sweden's 
contribution represented 17 per cent of the total. 
This proportion declined to 10 per cent by 1981; in 
1982 it was nearly 13 per cent and in 1983 slightly 
below 8 per cent of the Programme budget. 
The Programme has stressed the importance of at 
least maintaining its activities at current levels, 
in order to preserve the operational efficiency now 
attained. Within a few years, further resources are 
expected to be required for expensive field trials of 
new drugs and ' vaccines. The Programme's financial 
prospects now appear somewhat brighter than they 
were, thanks to larger contributions from the USA, 
but its management points out that activities are 
already severely restricted by lack of funds. 
Promising projects cannot be supported in a desirable 
way, and as a result research results are delayed. 
Too many applications for research grants from 
institutions in developing countries have had to be 
rejected. 
Where Programme finances are concerned, Sweden has 
urged that earmarked contributions be ruled out. 
This has become an established principle which, how- 
ever, has recently been questioned, since earmarked 
grants are considered easier to obtain. The Swedish 
attitude up to now has been that this would seriously 
affect the Programme's independent priorities, and 
this view was discussed at the 1985 meeting with JCB. 
The Programme is currently studying the question. 
The proportion of administrative costs in the total 
budget is shown in the figure below, from the latest 
annual report, to be less than 10 per cent. 
Figure 2 
Budget for various tvnes of expenditure. 1982-83 
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3 SUMMARY: ASSESSMENT AND CONCLUSIONS 
The Programme can now look back on almost a decade In 
operation. With some exceptions, activities have 
yielded good results, in some respects probably 
exceeding original expectations. The Programme has 
opportunely focused the attention of the 
international research community on six previously 
neglected diseases, all of which pose severe health 
problems in countries where they are endemic. 
Research on these diseases was to a large extent 
favoured by the rapid advance of biotechnology which 
took place shortly after the Programme's inception. 
With the exploitation of modem techniques, 
remarkably fast progress has been made in the 
development of vaccines against malaria and leprosy. 
Other effective compounds for controlling these 
diseases are being developed, and modem methods of 
identifying and typing infective agents greatly 
assist the work of surveying their incidence and 
extent. New drugs have emerged since Programme 
activities started and now await testing in field 
trials. Much of the rapid development of research 
relating to the six target diseases has come about 
outside the Programme, but the latter's catalytic and 
co-ordinating role is indisputable. 
The build-up and continued evolution of the Pro- 
gramme correspond in many ways to SAREC's research- 
funding principles. Sweden has pressed for the 
extension of research activities to cover the 
ecological, social and economic contexts of the 
diseases. Sweden has also emphasised the value of 
initiating and supporting operational and 
epidemiological research within the framework of the 
endemic countries' own control programmes, especially 
in view of the consolidation of national research 
capability in this respect. Sweden has laid 
particular emphasis on the Programme's second malor 
objective, which is in accord with SAREC's, urging 
that a large part of the budget should go towards 
capability-strengthening activities. This stand has 
involved controversy with certain other 
industrialised countries, which consider the first 
objective more important and believe any alternative 
policy will lower the quality of technical research. 
In certain fields, such as immunology, the bulk of 
research has been conducted in industrialised 
countries, and this has been conducive to rapid 
development. About 25 per cent of the Programme 
budget goes on strengthening the research capability 
of developing countries; a growing number of research 
projects are based in developing countries and run by 
indigenous researchers. 
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The latest annual report states that in the period 
1975-1984 the Programme awarded grants to about 2,300 
projects, of which just over 1,300 were conducted at 
institutions in endemic developing countries. One 
way of gauging the results of this research is to 
estimate the number of articles or reports published 
in scientific journals, monograph series, etc. By 
the end of 1984, more than 3,800 articles had been 
published and a further 420 were being printed. Of 
all the publications, half had appeared in 1983/84 - 
roughly the same number in industrial and developing 
countries. The estimated number of theses - Ph.D. 
and M.Sc. - backed by Programme grants in the period 
1975-84 is 146. Since SAREC funds about 10 per cent 
of Programme activities, the result may be estimated 
at about 230 projects and 380 publications. These 
figures should be compared with the number of pro- 
jects and publications relating to the six target 
diseases for which SAREC provides funds in the course 
of its other activities - direct, bilateral co- 
operation with individual countries and projects 
arising from Swedish applications. In that case, the 
cost to SAREC of administering these projects should 
be included. 
Some critical views of Programme research may 
justifiably be expressed. The pace of research on 
the diseases caused by filaria has been markedly 
slow. However, this appears to reflect biological 
problems: the parasites in question are adept at 
evading the host organism's defence mechanisms and 
not easily neutralised by drugs. Nonetheless, there 
have been some recent successes, and there are solid 
grounds for continuing Programme activities in this 
field. There does not seem to be much potential for 
further development of the vector-control component, 
and the disease-specific components would probably 
perform its tasks better. (App. 9). 
The second objective of the Programme has been to 
strengthen research capability in countries where one 
or more of the six target diseases are endemic. This 
objective has been more difficult to fulfil. A real- 
istic view of the problems involved has been adopted 
and an effort made to approach them with an awareness 
of the cultural, social and economic features of 
countries obtaining Programme support. Increasingly, 
an attempt is being made to create regional networks 
of institutions with which co-operation is feasible; 
this appears to be a strategy yielding good results. 
The greatest difficulties have been encountered in 
Africa, while the Programme has achieved considerable 
success with its capability-strengthening activities 
in South-East Asia and Latin America. It is essen- 
tial for institutions in endemic areas to be included 
at the earliest possible opportunity in international 
/ 
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networks and incorporated into the specific disease- 
oriented programmes. 
Nevertheless, it is clear that the major field 
trials planned for the evaluation of new vaccines 
against leprosy and malaria, and of new drugs, will 
not easily find donors outside the Programme, and 
that the Programme will therefore be faced with 
financial problems in the next few years. 
The importance of a coherent programme for tackling 
the target diseases - including socio-economic and 
epidemiological expertise - must be emphasised 
strongly, since research in the field of tropical 
medicine has neglected the latter fields. The epi- 
demiological and socio-economic components are in 
need of further reinforcement. Both the Programme's 
objectives - basic and applied interdisciplinary 
research, and support to the strengthening of capab- 
ility in developing countries - are unique, and its 
role in pursuing them would be hard to replace. 
The chronoloeical perspective of the Programme 
should be assessed for each of the various research 
fields supported. For the majority, termination of 
the Programme would mean serious setbacks to research 
on the diseases concerned. In recent years, the Pro- 
gramme has also acquired more of a co-ordinating and 
catalytic role, which is felt to be crucial. Its 
continuation as a united whole for a further ten-year 
period would appear to be a reasonable goal. The 
current capacity of the regular WHO organisation to 
take over Programme-backed research activities is 
extremely inadequate. 
SAREC is justified in taking up discussions with 
WHO on a long-term schedule for the take-over of 
Programme activities. Certain elements of the Pro- 
gramme, for example leprosy research activities, are 
run jointly by the Programme and the regular WHO 
organisation. A gradual Increase in WHO's financial 
and manpower responsibilities for the Programme 
should be possible. However, this presupposes 
expanded and modified WHO activities at central, 
regional and national levels. One reason why the 
special research programmes were established was 
that, as mentioned above, the regular WHO organisa- 
tion lacked the capacity to assume responsibility for 
research programmes. A gradual take-over of Pro- 
gramme activities by WHO therefore presupposes both 
policy decisions by the World Health Assembly and 
time for WHO to alter its organisational structure. 
An expansion at regional and national level has 
begun, but is bound to take time. Another precondi- 
tion is the transfer of extra funds to WHO's regional 
and national organisation. 
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For a number of years, SAREC has supported several 
different research programmes in WHO. The Special 
Programme, owing to its dual purpose - research and 
the strengthening of capability - has concentrated 
heavily on the implementation of research results in 
the endemic countries concerned. In recent years, 
owing to lack of funds, the Programme has been unable 
to support a number of institutions in more poverty- 
stricken developing countries. There is reason to 
stress the need for supplementary backing of research 
on tropical diseases. Such backing may comprise 
grants to national university and research institu- 
tions or to health care authorities' research pro- 
grammes for the development, adaptation and exploit- 
ation of research results, and could be given as part 
of SAREC's direct, bilateral co-operation with other 
countries. By the same- token, greater use may be 
made of Swedish, Scandinavian and/or other institu- 
tional resources. The potential for collaboration 
with Swedish foreign aid authorities - both SAREC and 
SIDA (the Swedish International Development Author- 
ity) - should be expanded. 
One example of SAREC-backed co-operation of this 
kind is the Programme's grant - initiated by SAREC - 
to the medical faculty of the Somali National Univer- 
sity. Experience from Programme-funded malaria 
research in several countries shows that there is a 
paramount need to build up resources for field 
studies in the endemic countries and also financial 
and other support, e.g. for personnel training. SIDA 
funds certain field research programmes on malaria 
and leprosy in India, but the Special Programme has 
found it difficult to devise channels of similar 
support in that country, although discussions with 
the Indian authorities are now under way. Increased 
co-operation between SAREC, SIDA and the Programme in 
India and, perhaps, other countries within the sphere 
of field studies, for example, is highly desirable. 
The Programme has concentrated on networks to streng- 
then contacts between research institutions in the 
same regions. These networks should be surveyed in 
the countries with which SAREC collaborates, so as to 
identify possible ways of further reinforcing and/or 
supplementing co-operation with the Programme. Con- 
tact with SIDA should be retained for the co- 
ordination of various efforts. Discussions must 
continue on the forms and content of any closer co- 
operation between SIDA and SAREC. 
SAREC thus has reason to investigate more closely 
how the results of Programme-funded research in 
various fields reach the consumers concerned. The 
stage prior to local application of research results 
may be further exemplified with reference to malaria: 
here, the need is for continued testing of various 
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anti-malarial drugs and for vector-control measures, 
I.e. the Introduction of special larvivorous fish and 
experiments with special insecticide-spraying 
devices. 
In-depth knowledge accruing from the special epi- 
demiological and socio-economic research components 
of the Programme where mapping, prevention and con- 
trol of the six diseases are concerned must be 
adapted to local needs. SAREC should give particular 
support to these components, which have hitherto been 
weak elements of most national programmes in the 
endemic countries. 
The annual Swedish contribution to the Programme in 
the last few years has been MSEK 13. An write-up to 
MSEK 16 annually for the next two years appears to be 
advisable owing both to the Programme's extensive 
needs for costly field studies in the years to come 
and to the decline in real terms due to the falling 
value of the Swedish krona. At the same time surveys 
should be conducted, in the countries supported by 
SAREC, of further resource requirements to permit 
exploitation and adaptation of the technology which 
has emerged under the aegis of the Programme. The 
SAREC-Special Programme co-operation model created in 
Somalia should serve as a lodestar for SAREC1s 
continued studies of support at national level. 
